TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07675629: Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Sponsor: Worcester HIV Vaccine · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 126 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07675629 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07675629 Rescue Dossier →